Biogen stock ( NASDAQ:BIIB ) has been volatile in recent years, with much riding on the success of the company’s Alzheimer’s medicines. This is partly due to Biogen’s need for a blockbuster drug to rally behind. Sales have been falling in recent years, and the loss of patent protection for the top-selling multiple sclerosis drug Tecfidera is increasing those fears.
What will Biogen’s business look like in the next five years? Is it promising enough for investors to purchase Biogen stock ( NASDAQ:BIIB ) now?
Biogen Stock: A lot is Riding on Lecanemab.
When it comes to biotechs, every firm needs a viable solution that can be built around – and that can entice investors. Biogen had great expectations for Alzheimer’s drug Aduhelm, but it seems to be a disappointment, failing to get approval from health regulators and even Medicare, which would not pay it unless patients use it as part of a research study.
Enter lecanemab , a promising medication that might become a blockbuster Alzheimer’s medicine, reviving Biogen’s company. The significant distinction is that Aduhelm received fast FDA clearance because of its potential to lower amyloid-beta plaque, which is expected to aid Alzheimer’s sufferers. However, opinions on the outcome differ.
JPMorgan analysts estimate that lecanemab may generate up to $10 billion in revenue if completely authorized. Although Biogen will have to split revenues with its partner, Japanese pharmaceutical Eisai (OTC:ESALY), the deal might be a big gain for the company. <...
Click here to read the full article on PressReach.com .Subscribe to the PressReach RSS feeds:
- Featured News RSS feed
- Investing News RSS feed
- Daily Press Releases RSS feed
- Trading Tips RSS feed
- Investing Videos RSS feed
Follow PressReach on Twitter
Follow PressReach on TikTok
Follow PressReach on Instagram
Subscribe to us on Youtube